Kyoto Univ: Providing “clinical IPS cells” overseas: Korean venture company
Kyoto University iPS Cell Research Foundation:
We provided clinical iPS cells overseas for the first time.
Clinical iPS cells:
It becomes various tissues and cells and is used for research on treatment methods for intractable diseases.
It is difficult to make it except for the “Kyoto University iPS Cell Research Foundation”, which has a large number of researchers and is well equipped.
Provided to Korean venture companies:
According to the Foundation, it has never been offered overseas.
Last month, we provided it to a Korean venture company.
Korean and Japanese constitution:
Koreans have similar cell properties to Japanese.
It turned out that rejection is unlikely to occur when transplanted.
President Yamanaka:
We would like to continue these efforts for clinical application.
News | Kansai Telecasting
https://www.ktv.jp/news/articles/27d952d4_7d45_44bc_a247_9d4636d50c59.html
A Bridge from Japan to Korea:
CiRA Foundation’s First Provision of Clinical-Grade iPS Cell Stock
News | CiRA Foundation
Key Points
CiRA Foundation®(“CiRA_F” located in Kyoto, Japan) has provided the clinical-grade iPS cell stock (iPSC stock) to iPS Bio, Inc (“iPS Bio” located in Pangyo, Korea).
This is the first time
that CiRA_F has provided the clinical-grade iPSC stock to an overseas.iPS Bio plans to conduct clinical trials
using GMP-grade iPSC products for treating Huntington’s disease, stroke, Alzheimer’s disease, as well as immune-oncology diseases, in the next few years.
Based on this incredible collaboration with iPS Bio,
CiRA_F will make further efforts to manufacture high-quality iPSC stock
for regenerative medicine to meet global standards,and will continue to contribute to the practical application of iPS cell technology through providing the iPSC stock to global partners of CiRA_F such as iPS Bio.
To accomplish the ultimate goal of “providing the top iPS cell technologies at affordable prices,
“CiRA_F has been supplying iPSC stock, SOPs, and quality evaluation services for regenerative medicine.
CiRA_F is always open to collaborating with partners.
News | CiRA Foundation